157 related articles for article (PubMed ID: 31654628)
1. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
3. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
9. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
[TBL] [Abstract][Full Text] [Related]
13. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
15. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy.
Ohno A; Iwata T; Katoh Y; Taniguchi S; Tanaka K; Nishio H; Nakamura M; Morisada T; Chen G; Saito M; Yaguchi T; Kawakami Y; Aoki D
Gynecol Oncol; 2020 Nov; 159(2):329-334. PubMed ID: 32829964
[TBL] [Abstract][Full Text] [Related]
17. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
[TBL] [Abstract][Full Text] [Related]
18. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
19. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
